Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 9/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26027087 | 0.92 | FURIN (0.40) | FURINROCK2CTSLFOLH1KLKB1 | |
| SCHEMBL26027085 | 0.92 | KLKB1 (0.43) | FURINROCK2CTSLKLKB1 | |
| SCHEMBL25363108 | 0.90 | FURIN (0.38) | SIRT5FURINROCK2CHRNA1CHRNG | |
| SCHEMBL26026790 | 0.90 | FURIN (0.38) | SIRT5FURINROCK2CHRNA1CHRNG | |
| SCHEMBL25363100 | 0.90 | FURIN (0.38) | SIRT5FURINROCK2CHRNA1CHRNG | |
| SCHEMBL26026941 | 0.88 | FURIN (0.35) | FURINROCK2CTSL | |
| SCHEMBL25361536 | 0.86 | SIRT5 (0.38) | SIRT5FURINFOLH1SIRT1 | |
| SCHEMBL25361554 | 0.86 | SIRT5 (0.38) | SIRT5FURINFOLH1SIRT1 | |
| SCHEMBL25438103 | 0.85 | CTSL (0.41) | FURINROCK2CTSLKLKB1 | |
| SCHEMBL24390287 | 0.85 | FURIN (0.38) | SIRT5FURINROCK2CTSLKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SIRT5 2004/4885FURIN 2087/4885ROCK2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.